Shire's Vyvanse Will Attain Blockbuster Status by 2017 in the Attention-Deficit/Hyperactivity Disorder Drug Market
Emerging Nonstimulant Drugs Will Earn Less Than 15 Percent Share of the ADHD Market in 2017, According to a New Report from Decision Resources
30-Sep-2008 -
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that Shire's recently launched stimulant Vyvanse will become only the third blockbuster in attention-deficit/hyperactivity disorder (ADHD), helping to ensure that Shire's impressive ADHD portfolio ...
Germany
Italy
Shire
+1